

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

For Immediate Release:

Nymox Product a Tool for Smoking Cessation Efforts

Nymox's NicAlert™ Enables On-Site Testing of Smoking Status

HASBROUCK HEIGHTS, NJ (November 17, 2006) November 16 is the American Cancer Society's Great American Smokeout, when smokers across the U.S. are encouraged to butt out for the day and hopefully for good. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) offers its NicAlert™ products which allow concerned individuals the ability to perform an on-the-spot evaluation of smoking status. NicAlert™ has been successfully used in many studies of smoking status and in smoking cessation and harm reduction campaigns in the U.S. and in Europe and is currently being used in a large smoking cessation study in collaboration with g-Nostics Ltd. in the U.K.

NicAlert™ can be used with either urine or saliva samples to provide an accurate visual read-out on a person's tobacco use or exposure within minutes. No instruments or special training is required for its use. NicAlert™ Saliva, the saliva-based version of NicAlert™, recently achieved certification with the CE Mark, permitting its sale in the European Union. The urine-based version of NicAlert™ earlier received clearance from the U.S. Food and Drug Administration, and also achieved European certification with the CE Mark.

NicAlert™ was recently used in a study by researchers at the Centers for Disease Control and Prevention (CDC) (*Journal of Analytical Toxicology* 2005; 29: 814-818), where NicAlert™ measurements were found to correlate well with the far more complex laboratory testing (liquid chromatography-mass spectrometry) used in the CDC laboratory.

Other independent peer-reviewed studies in the clinic have also found the technology employed in NicAlert™ to be accurate, rapid and cost-effective. One study, (*Cancer Epidemiology, Biomarkers & Prevention* 2002; 11: 1123-1125) found that the results obtained using Nymox's tobacco product exposure test had an "excellent agreement" with state-of-the-art sophisticated laboratory measurements but at a substantially lower cost (over 90% less). Another study, (*Nicotine & Tobacco Research* 2002; 4: 305-9) found Nymox's product to be "an inexpensive and rapid method to routinely biochemically confirm smoking status at a clinical visit."

Cigarette smoking is the single most preventable cause of premature death in the United States. Each year, over 400,000 people die as a result of tobacco use and exposure in the U.S. alone. Smoking is of particular concern for pregnant women. Smoking during pregnancy is known to increase the risk of pregnancy complications, premature delivery, low-birth-weight infants, stillbirth, and sudden infant death syndrome (SIDS).

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.